ANMAT Updates Bioequivalence Study requirements for Oral Hypoglycemic Drugs
Buenos Aires, Argentina – January 20, 2026 – The National Management of Medicines, Food and Medical Technology (ANMAT) has announced significant modifications to the list of medicinal specialties required to undergo bioavailability and bioequivalence studies. These changes, detailed in Provision 47/2026 published today in the Official Gazette, specifically target oral hypoglycemic agents categorized as Class II and IV active pharmaceutical ingredients (APIs) according to the Biopharmaceutical Classification System.
The updated list of affected medicinal specialties is available in annex I of Provision 47/2026, while Annex II identifies the corresponding reference products to be used for comparison. This regulatory update is crucial for pharmaceutical laboratories manufacturing and distributing these medications within Argentina.
ANMAT has established a strict 180-day deadline, commencing from the effective date of the Provision, for laboratories to submit the results of the required bioequivalence studies. Failure to present these results within the stipulated timeframe, or if the submitted data fails to demonstrate bioequivalence to the reference product, will result in the immediate suspension of marketing authorization for the implicated medicinal specialties – without prior notification.
Recognizing potential efficiencies, ANMAT allows laboratories holding medicinal specialties with APIs listed in Annex I to demonstrate equivalence through in vitro studies, provided their formulations exhibit proportional similarity to a multisource product already proven bioequivalent to the reference product. this offers a potentially streamlined pathway to compliance for certain formulations.
This regulatory action underscores ANMATS commitment to ensuring the quality, safety, and efficacy of pharmaceutical products available to the Argentine public. Pharmaceutical companies are urged to review Provision 47/2026 in its entirety and proactively address the new requirements to maintain market access for their oral hypoglycemic medications.
Keywords: ANMAT, Bioequivalence, bioavailability, Oral Hypoglycemic Agents, Pharmaceuticals, Argentina, Provision 47/2026, Drug Regulation, Pharmaceutical Compliance, API, Reference Products, Marketing Authorization, In Vitro Studies.